REMODULIN Drug Patent Profile
✉ Email this page to a colleague
When do Remodulin patents expire, and when can generic versions of Remodulin launch?
Remodulin is a drug marketed by United Therap and is included in two NDAs. There are ten patents protecting this drug and two Paragraph IV challenges.
This drug has sixty-four patent family members in nine countries.
The generic ingredient in REMODULIN is treprostinil. There are nineteen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the treprostinil profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Remodulin
A generic version of REMODULIN was approved as treprostinil by SANDOZ on November 30th, 2017.
Summary for REMODULIN
International Patents: | 64 |
US Patents: | 10 |
Applicants: | 1 |
NDAs: | 2 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 100 |
Clinical Trials: | 30 |
Patent Applications: | 2,146 |
Drug Prices: | Drug price information for REMODULIN |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for REMODULIN |
What excipients (inactive ingredients) are in REMODULIN? | REMODULIN excipients list |
DailyMed Link: | REMODULIN at DailyMed |
Recent Clinical Trials for REMODULIN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Lung Biotechnology PBC | Phase 4 |
University of Rhode Island | Phase 1/Phase 2 |
United Therapeutics | Phase 1/Phase 2 |
Pharmacology for REMODULIN
Drug Class | Prostacycline Vasodilator |
Physiological Effect | Vasodilation |
Anatomical Therapeutic Chemical (ATC) Classes for REMODULIN
Paragraph IV (Patent) Challenges for REMODULIN
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
REMODULIN | Injection | treprostinil | 1 mg/mL, 2.5 mg/mL, and 5 mg/mL, 20 mL vial | 021272 | 1 | 2012-12-07 |
REMODULIN | Injection | treprostinil | 10 mg/mL, 20 mL vial | 021272 | 1 | 2011-12-02 |
US Patents and Regulatory Information for REMODULIN
REMODULIN is protected by ten US patents.
Patents protecting REMODULIN
Inhalation formulations of Treprostinil
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Inhalation formulations of treprostinil
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: A METHOD OF TREATING A HUMAN PATIENT SUFFERING FROM PULMONARY HYPERTENSION
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE DILUENT FOR FLOLAN OR STERILE DILUENT FOR EPOPROSTENOL SODIUM PRIOR TO ADMINISTRATION
Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE DILUENT FOR FLOLAN OR STERILE DILUENT FOR EPOPROSTENOL SODIUM PRIOR TO ADMINISTRATION
Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE DILUENT FOR FLOLAN OR STERILE DILUENT FOR EPOPROSTENOL SODIUM PRIOR TO ADMINISTRATION
Compounds and methods for delivery of prostacyclin analogs
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE WATER FOR INJECTION OR 0.9% SODIUM CHLORIDEINJECTION PRIOR TO ADMINISTRATION
Process to prepare treprostinil, the active ingredient in remodulin.RTM.
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Process to prepare treprostinil, the active ingredient in Remodulin.RTM.
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Parenteral formulations of treprostinil
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: A METHOD OF TREATING PULMONARY HYPERTENSION COMPRISING PARENTERALLY ADMINISTERING A FORMULATION COMPRISING A) 0.1 TO 5% W/V OF TREPROSTINIL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND B) A CITRATE BUFFER
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
United Therap | REMODULIN | treprostinil | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | 208276-001 | Jul 30, 2018 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
United Therap | REMODULIN | treprostinil | INJECTABLE;IV (INFUSION), SUBCUTANEOUS | 021272-002 | May 21, 2002 | AP | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
United Therap | REMODULIN | treprostinil | INJECTABLE;IV (INFUSION), SUBCUTANEOUS | 021272-002 | May 21, 2002 | AP | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
United Therap | REMODULIN | treprostinil | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | 208276-004 | Jul 30, 2018 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for REMODULIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
United Therap | REMODULIN | treprostinil | INJECTABLE;IV (INFUSION), SUBCUTANEOUS | 021272-001 | May 21, 2002 | ⤷ Try a Trial | ⤷ Try a Trial |
United Therap | REMODULIN | treprostinil | INJECTABLE;IV (INFUSION), SUBCUTANEOUS | 021272-002 | May 21, 2002 | ⤷ Try a Trial | ⤷ Try a Trial |
United Therap | REMODULIN | treprostinil | INJECTABLE;IV (INFUSION), SUBCUTANEOUS | 021272-004 | May 21, 2002 | ⤷ Try a Trial | ⤷ Try a Trial |
United Therap | REMODULIN | treprostinil | INJECTABLE;IV (INFUSION), SUBCUTANEOUS | 021272-004 | May 21, 2002 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for REMODULIN
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
SciPharm Sàrl | Trepulmix | treprostinil | EMEA/H/C/005207 Treatment of adult patients with WHO Functional Class (FC) III or IV and:inoperable chronic thromboembolic pulmonary hypertension (CTEPH), orpersistent or recurrent CTEPH after surgical treatmentto improve exercise capacity. |
Authorised | no | no | yes | 2020-04-03 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for REMODULIN
See the table below for patents covering REMODULIN around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
World Intellectual Property Organization (WIPO) | 9921830 | ⤷ Try a Trial | |
South Korea | 100447022 | ⤷ Try a Trial | |
Hungary | 207220 | PROCESS FOR PRODUCING PHARMACEUTICAL COMPOSITION FOR DIMINISHING ENHANCED PRESSURE OF THE PULMONARY CIRCULATION | ⤷ Try a Trial |
South Korea | 20060021862 | COMPOUNDS AND METHODS FOR DELIVERY OF PROSTACYCLIN ANALOGS | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |